Maravai LifeSciences Holdings, Inc.
NASDAQ•MRVI
CEO: Mr. William E. Martin III
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-11-20
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Contact Information
Market Cap
$1.08B
P/E (TTM)
-4.7
38.2
Dividend Yield
--
52W High
$6.05
52W Low
$1.67
52W Range
Rank40Top 42.0%
4.1
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Average • 4.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025
Financial Dashboard
Q3 2025 Data
Revenue
$41.63M-36.15%
4-Quarter Trend
EPS
$0.48-168.57%
4-Quarter Trend
FCF
-$18.08M-609.90%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revenue Drops Significantly Total revenue $135.9M (9M 2025), down 32.9% from $202.6M in prior period due to lost CleanCap sales.
Gross Margin Compression Severe Gross profit margin fell to 13.6% (3M 2025) from 46.7% (3M 2024); 9M margin 15.6% versus 43.9%.
Impairment Charges Reduced Goodwill impairment totaled $42.9M (9M 2025), a significant decrease from $154.2M recorded in the nine months ended September 2024.
Cash Position Remains Strong Cash and cash equivalents stood at $243.6M as of September 30, 2025, supporting liquidity needs for the near term.
Risk Factors
High-Volume Sales Absent Revenue decline driven by lack of recurring high-volume CleanCap orders; 9M 2024 included $51.6M in such sales.
Restructuring Costs Expected Implemented 2025 Corporate Realignment Plan, expecting $5.3M cash payments through H1 2026; further facility costs unknown.
Goodwill Impairment Indicators Present TriLink unit impaired due to lower forecast revenues; Alphazyme unit also impaired based on lower enzyme product demand.
Geopolitical Economic Headwinds Businesses face headwinds from general economic contraction in Asia, especially China, and ongoing geopolitical trade uncertainty.
Outlook
Realignment Cost Savings Target 2025 Corporate Realignment Plan aims to lower annualized operating expenses by over $50.0M through headcount reductions.
Integrating Recent Acquisitions Focus on integrating Molecular Assemblies and Officinae Bio assets to vertically integrate supply chain and expand product offerings.
R&D Investment Continuation Intends to continue disciplined investments in infrastructure and new products/technologies to support long-term customer needs.
Cash Sufficient for 12 Months Existing cash and credit access expected to satisfy cash requirements over the next 12 months and beyond.
Peer Comparison
Revenue (TTM)
IOVA$250.43M
$192.28M
DNA$180.61M
Gross Margin (Latest Quarter)
100.0%
IOVA97.9%
PHAT87.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| EYPT | $1.25B | -5.1 | -76.1% | 8.5% |
| PHAT | $1.10B | -3.8 | 77.3% | 1.1% |
| MRVI | $1.08B | -4.7 | -42.6% | 4.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-9.6%
Growth Under Pressure
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 17, 2026
EPS:-$0.07
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 7, 2025|Revenue: $41.63M-36.1%|EPS: $0.48-168.6%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 11, 2025|Revenue: $47.40M-35.4%|EPS: $-0.27+383.9%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 12, 2025|Revenue: $46.85M-27.0%|EPS: $-0.21+130.0%MissForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 18, 2025|Revenue: $259.19M-10.3%|EPS: $-1.05-16.7%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 12, 2024|Revenue: $65.20M-2.5%|EPS: $-0.70+1328.6%MissForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 8, 2024|Revenue: $73.40M+6.5%|EPS: $-0.06+12.5%MissForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 9, 2024|Revenue: $64.18M-18.8%|EPS: $-0.09+795.1%MissForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 29, 2024|Revenue: $288.95M-67.3%|EPS: $-0.90-153.9%Miss